...
首页> 外文期刊>The breast journal >Correlation of her-2eu gene amplification with other prognostic and predictive factors in female breast carcinoma.
【24h】

Correlation of her-2eu gene amplification with other prognostic and predictive factors in female breast carcinoma.

机译:女性乳腺癌中her-2 / neu基因扩增与其他预后和预测因素的相关性。

获取原文
获取原文并翻译 | 示例

摘要

The purpose of this study was to determine if any relationship exists between Her-2eu gene amplification and estrogen receptor (ER), progesterone receptor (PR), MIB-1, grade, size and age in female breast cancer. Five hundred and eighteen female patients with invasive breast carcinoma, 390 ductal and 128 lobular, in which assessment of Her-2eu amplification by fluorescence in-situ hybridization (FISH) has been performed, were reviewed retrospectively. Each patient was further assessed for ER, PR, MIB-1, grade, size and age at diagnosis. Chi-square analysis was then used to correlate the above observations. Overall gene amplification was seen in 76 (15%) of the cases, 68 (17%) were ductal and 8 (6%) were lobular. Her-2eu gene was amplified in 37 (10%) out of 379 ER positive cases and in 39 (28%) out of 139 ER negative cases. Her-2eu was amplified in 22 (7%) out of 301 PR positive cases and in 54 (25%) out of 217 PR negative cases. Amplification occurred in 18 (8%) out of 222 negative MIB-1 casesand amplified in 58 (20%) out of 296 positive cases. Amplification was seen in 5 (10%) out of 49 grade I tumors, 17 (12%) out of 143 grade II tumors and 54 (27%) out of 198 grade III tumors. Lobular carcinomas were not graded. Amplification was present in 52 (15%) out of 346 T1 lesions, in 17 (13%) out of 130 T2 lesions, in 5 (17%) out of 30 T3 lesions and in 2 (17%) out of 12 T4 lesions. Her-2eu was amplified in 67 (14%) out of 467 woman 41 years and older, and in 9 (18%) out of 51 women 40 years and younger. Comparison of these frequencies using chi-square test revealed statistically significant correlation between Her-2eu amplification and ductal versus lobular carcinoma (p < 0.0003), ER (p = 0.0001) and PR (p < 0.0001) negative tumors, over-expression of MIB-1 (p < 0.0005) and high tumor grade (p = 0.0009), while size of the tumor (p = 0.08) and age of the patients (p = 0.67) were not statistically significant. Correlation was found between Her-2eu amplification and tumor type, high histological grade, ER and PR negative tumors, and high proliferative MIB-1 index. No correlation was found between size of the tumor and age of the patient with Her-2eu amplification.
机译:这项研究的目的是确定女性乳腺癌中Her-2 / neu基因扩增与雌激素受体(ER),孕激素受体(PR),MIB-1,等级,大小和年龄之间是否存在任何关系。回顾性分析了518例女性浸润性乳腺癌,390例导管癌和128例小叶癌患者,他们通过荧光原位杂交(FISH)评估了Her-2 / neu扩增。在诊断时进一步评估每位患者的ER,PR,MIB-1,等级,大小和年龄。然后,使用卡方分析来关联上述观察结果。在76例(15%)的病例中发现了整体基因扩增,其中68例(17%)为导管,8例(6%)为小叶。在379例ER阳性病例中,有37例(10%)和139例ER阴性病例中的39例(28%)扩增了Her-2 / neu基因。在301例PR阳性病例中,有22例(7%)扩增了Her-2 / neu,在217例PR阴性病例中,有54例(25%)扩增了Her-2 / neu。 222例MIB-1阴性病例中有18例(8%)发生扩增,而296例阳性MIB-1病例中有58例(20%)扩增。在49个I级肿瘤中有5个(10%),在143个II级肿瘤中有17个(12%)和在198个III级肿瘤中有54个(27%)可见扩增。小叶癌未分级。在346个T1病变中有52个(15%),在130个T2病变中有17个(13%),在30个T3病变中有5个(17%)和在12个T4病变中有2个(17%)存在扩增。在41岁及以上的467位女性中,有67位(14%)放大了Her-2 / neu,在40岁及以下的51位女性中,有9位(18%)放大了。使用卡方检验比较这些频率,发现Her-2 / neu扩增与导管癌与小叶癌(p <0.0003),ER(p = 0.0001)和PR(p <0.0001)阴性肿瘤,过表达之间存在统计学上的显着相关性MIB-1(p <0.0005)和高肿瘤分级(p = 0.0009)的发生率,而肿瘤大小(p = 0.08)和患者年龄(p = 0.67)没有统计学意义。发现Her-2 / neu扩增与肿瘤类型,高组织学等级,ER和PR阴性肿瘤以及高增殖MIB-1指数之间存在相关性。在Her-2 / neu扩增的情况下,在肿瘤大小与患者年龄之间未发现相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号